Ilmarinen Mutual Pension Insurance Co Buys 5,000 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Ilmarinen Mutual Pension Insurance Co lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 15,000 shares of the medical research company’s stock after purchasing an additional 5,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in IQVIA were worth $2,948,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter worth about $336,041,000. Raymond James Financial Inc. purchased a new stake in IQVIA in the 4th quarter worth approximately $236,120,000. American Century Companies Inc. boosted its holdings in IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after purchasing an additional 905,960 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Nordea Investment Management AB raised its position in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $154.63 on Friday. IQVIA Holdings Inc. has a 12 month low of $154.35 and a 12 month high of $252.88. The company has a market cap of $27.26 billion, a price-to-earnings ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50-day moving average price of $189.67 and a 200-day moving average price of $203.82.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on IQV. Bank of America reduced their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Truist Financial restated a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Morgan Stanley lifted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.